<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03996850</url>
  </required_header>
  <id_info>
    <org_study_id>18-001817</org_study_id>
    <secondary_id>NCI-2019-02711</secondary_id>
    <secondary_id>18-001817</secondary_id>
    <nct_id>NCT03996850</nct_id>
  </id_info>
  <brief_title>SPECT/CT for the Characterization of Renal Masses</brief_title>
  <official_title>SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well technetium Tc-99m sestamibi single-photon emission computed
      tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with
      kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a
      less invasive way to check for kidney tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the impact of technetium Tc-99m sestamibi (MIBI) SPECT/CT on patient
      management decisions.

      SECONDARY OBJECTIVES:

      I. To evaluate the impact of MIBI SPECT/CT on patient management decisions for tumors 1.5-3.0
      cm and 3.1-5.0 cm.

      II. To assess the impact of MIBI SPECT/CT on decisional conflict score. III. To assess the
      impact of MIBI SPECT/CT on physician management recommendation.

      IV. To evaluate the sensitivity and specificity of MIBI SPECT/CT for the identification of an
      oncocytic renal mass (oncocytoma, chromophobe, and hybrid oncocytic tumor) with respect to
      tumor histology identified by renal mass biopsy or surgical resection.

      V. To compare the specificity of MIBI SPECT/CT with conventional cross-sectional imaging in
      predicting an oncocytic renal mass.

      VI. To assess the correlation between MIBI SPECT/CT outcomes to final treatment decisions.

      EXPLORATORY OBJECTIVES:

      I. Evaluate the mitochondria content in tumors that had positive MIBI SPECT/CT findings.

      OUTLINE:

      Patients receive technetium Tc-99m sestamibi intravenously (IV) then undergo SPECT/CT.

      After completion of study, patients are followed up for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient management decision</measure>
    <time_frame>6 months</time_frame>
    <description>Assessed with post-test, physician counseling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decision making based on tumor size</measure>
    <time_frame>6 months</time_frame>
    <description>Could be differentially impacted in two strata, tumors 1.5-3.0 cm and 3.1-5.0 cm.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Kidney Neoplasm</condition>
  <condition>Renal Mass</condition>
  <arm_group>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <description>Patients receive technetium Tc-99m sestamibi IV then undergo SPECT/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <description>Undergo SPECT/CT</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <other_name>Medical Imaging, Single Photon Emission Computed Tomography</other_name>
    <other_name>Single Photon Emission Tomography</other_name>
    <other_name>single-photon emission computed tomography</other_name>
    <other_name>SPECT</other_name>
    <other_name>SPECT imaging</other_name>
    <other_name>SPECT SCAN</other_name>
    <other_name>SPET</other_name>
    <other_name>tomography, emission computed, single photon</other_name>
    <other_name>Tomography, Emission-Computed, Single-Photon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Technetium Tc-99m Sestamibi</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Health service research (MIBI SPECT/CT, questionnaire)</arm_group_label>
    <other_name>Cardiolite</other_name>
    <other_name>Miraluma</other_name>
    <other_name>Tc 99m Sestamibi</other_name>
    <other_name>Tc-99m MIBI</other_name>
    <other_name>Tc99m Sestamibi</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with new diagnosis of a renal tumor (within past 3 months)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Performance status Eastern Cooperative Oncology Group (ECOG) &lt; 2.

          -  Life expectancy (&gt; 1 year).

          -  New diagnosis of a renal tumor (within past 3 months).

          -  Measurable, predominantly (&gt; 80%) solid renal neoplasm between 1.5-5.0 cm.

          -  Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic
             resonance imaging (MRI).

          -  No definitive evidence of metastatic disease.

          -  Does not require urgent surgical treatment.

          -  Candidate for surgical, ablative, and surveillance approach.

          -  Willingness to obtain more information to aid decision-making.

          -  Understanding and willingness to provide consent.

        Exclusion Criteria:

          -  Presence of multiple solid renal tumors.

          -  A prior needle biopsy of the mass resulting in histologic diagnosis.

          -  A prior diagnosis of kidney cancer.

          -  Presence of an active, untreated, non-renal malignancy.

          -  History of bleeding diathesis or recent bleeding episode.

          -  Prior surgery or radiation therapy to the kidney.

          -  Unwillingness to fill out questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Shuch</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Shuch</last_name>
      <phone>310-794-7700</phone>
      <email>BShuch@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Shuch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

